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6INTRODUCTION 
 
INTRODUCTION 
Anaemia is defined by a decrease in haemoglobin 
concentration with a consequent decrease in the hematocrit. It is the 
most common medical disorder in pregnancy. The two most common 
cause of anaemia are iron deficiency and acute blood loss. (1) 
Depending on the severity of the blood loss anaemic 
postpartum patients can be at increased risk of morbidity and even 
mortality (2) and anaemia due to heavy bleeding during delivery 
should be corrected without delay. 
Anaemia is defined by World Health Organisation as 
haemoglobin levels <11 g/dl. It is one of the most serious global 
public health problems, affecting 52% of pregnant women in 
developing and 23% of the developed countries. (3) 
 
Iron is an essential component of haemoglobin in the blood.  
The pregnant woman needs 1000mg of iron all through her 
pregnancy i.e. 3-5 mg/day to maintain iron balance. This demand 
during later half of pregnancy and for several weeks after delivery 
increases to 6.7 mg/day. (4) 
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The absorption of iron from oral supplements is influenced by 
the dose; the patients iron stores and intake in relation to meal time. 
Parentral administration of iron, as an alternative provides a quick 
and certain correction of total iron deficit. (5) 
A complete workup is essential, preferably with 
haematological indices such as hypochromic and microcytic red 
cells and reticulocytes classified by degree of maturity in particular 
before parentral therapy is given. (6) 
Traditional therapy which is based on either oral 
administration of iron or blood transfusion has had many draw backs. 
Efficacy of oral iron is limited due to high incidence of side effects 
and non-compliance where as blood transfusion is associated with the 
risk of infection, immunologic impact and transfusion reactions. (6) 
Modern alternative strategies call for parentral administration 
of new, well tolerated iron preparation e.g., iron sucrose which has 
been successfully used in the treatment of postpartum anaemia and 
increasingly during 2nd and 3rd trimester of pregnancy. (6) 
This study was done to find out the efficacy and safety of 
intravenous iron sucrose in the treatment of iron deficiency anaemia 
in the postpartum period. 
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9REVIEW OF LITERATURE 
 
REVIEW OF LITERATURE 
International journal of gynaec and obstetrics (2005) 90,238-
239. A.Dede, D.Uygus, B.Yilmaz T.mungan, M.Ugur conducted a 
study to compare the safety and efficacy of intravenous iron 
sucrose complex in the treatment of iron deficiency anaemia during 
puerperium. The study population had 75 women older than 18 
years whose haemoglobin were <= 9g/dl after delivery whether 
vaginal or caesarean. The participants were assigned to 2 groups. In 
the intravenous group, n=50 the total iron sucrose dose was 
administered as calculated. Those receiving oral treatment (n=25) 
were given 300 mg tablets of iron sulphate (each containing 60mg 
elemental iron) 1hour before meals three times a day. Blood 
samples were taken before the start of therapy and at days 7 and 28 
to evaluate Hb%, serum ferritin, serum iron and CRP as well as 
hematocrit, mean corpuscular volume (MCV) and total serum iron 
binding capacity. 
 In conclusion, intravenous iron therapy with iron sucrose 
complex significantly increased serum ferritin level within a short 
time with fewer side effects than oral iron therapy in women with 
postpartum iron deficiency anaemia. 
10
 
British journal of Obstetrics and Gynaecology, Sep 2006; 
1248-1252. Bhandal.N.Russell. R carried out a prospective 
randomised trial enrolling 44 women with iron deficiency anaemia, 
defined as Hb < 9gm/dl when measured 24 to 48 hrs after delivery. 
Group A received (N.22) 200mg I.V on days 2 and 4. Group B (N. 
22) received 200mg of oral ferrous sulphate twice a day for 6 wks. 
Average rise in Hb was 2.5gm/dl on day 5 in I.V group and 
0.7gm/dl in oral group. There were no serious adverse effects in I.V 
group except a few who reported facial flushing and metallic taste 
during iron infusion. 1/3 of women in oral group had 
gastrointestinal side effects. They concluded that in women with 
postpartum iron deficiency anaemia intravenous iron sucrose 
produces higher blood Hb level than oral iron supplementation.  
C Giannoulis, A Danniilides, T Tantanasis, K Dinas, and J 
Tzafettas. Intravenous administration of iron sucrose for treating 
anaemia in postpartum women. Hippokratia, 2009 Jan – Mar: 13(1): 
38 – 40.  The prsopective study was conducted in one hundred and 
four postpartum women. The criteria for the diagnosis of anaemia 
were Hb <8 g/dl and ferritin < 10µg/dl. They were randomised into 
two groups. Group A consisted of 78 women who received i.v a 
total amount of 300mg iron sucrose in three days. Group B 
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consisted of 26 women who received orally 800 mg iron protein 
succinylate daily for four weeks. At the end of study, in group A 
the increase in Hb mean level was 4.6 g/dl and of ferritin mean 
level was 105 mg/l. In group B the increase in Hb mean level was 
2.3 g/dl and ferritin level was 68 mg/dl. The significant difference 
in the increase of haemoglobin level (p=0.0001) and also in the 
increase in ferritin level (p=0.0004) between the two groups. 
 Lippincott Williams and Wilkins Inc, Pakistan institute 
of medical science conducted a randomised controlled study in 80 
patients with gestational age of 12 – 36 wks from antenatal clinic 
and 20 patients after postpartum haemorrhage with anaemia. Group 
A received I.V. iron sucrose; group B received I.M iron sorbitol. 
Group A had mean Hb content of 1.3 + 1.1 gm/dl and group B had 
7.9 + 0.9 gm/dl. Three weeks post therapy assessment of Hb 
showed a total rise of 2.6 gm/dl (Group A) and 1.2 gm/dl (Group 
B). Target Hb i.e. 11gm/dl was achieved in 80% of group A and 
20% of group B Patients. Blood transfusion was not required in any 
group. They concluded that intravenous iron sucrose is safe, 
convenient and more effective than intramuscular iron therapy in 
treatment of Iron deficiency anaemia during pregnancy. It can 
minimise blood transfusion in postnatal women. 
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scoff b. silverstein and george rodgers  
The increased availability of parentral iron preparation should 
decrease the need to use red cell transfusion in patients with iron 
deficiency anaemia. They observed that increase in Hb is noted 
after one week of iron sucrose administration and serious 
anaphylactic hypersensitivity of 0.002% in i,v iron sucrose group 
compared to 0.6-0.7% in i,m iron dextran group. 
Gravier A, Descargues G, Marpeace L et al (1999) conducted 
a study on how to avoid postpartum blood transfusions in Iron 
deficiency anaemia patients, by treating with I.V Iron sucrose. They 
concluded that I.V Iron sucrose is effective in preventing 
unnecessary blood transfusions in postpartum patients. 
Al Momen et al conducted a prospective, open-label 
controlled trial in 111 pregnant women with iron deficiency 
anaemia (Hb : <9gm/dl) and divided into 2 groups. Intravenous 
group and intramuscular group. Intravenous iron sucrose was 
administered as an infusion of single 100mg dose in normal saline 
every 1 to 3 days. 
 Controls received I.M iron dextran (100mg on alternate 
days) till the calculated dose was reached. Intravenous iron therapy 
13
 
resulted in higher levels of Hb, with the time to achieve maximum 
Hb in shorter period compared with controls. No serious adverse 
effects were noted in iron sucrose group whereas 6% of patients 
could not tolerate I.M iron dextran, who were excluded from the 
study. 30% of patients in the control group had disturbing G1 
symptoms and 32% were non complaint. 
Wali A, MushtaqA, Nilofer.(Journal Pakistan med. Assoc. 
2002 sep 52(9): 392 – 5) 
A prospective comparative study, total number of 60 pregnant 
women with gestational age of 12 – 34 wks with iron deficiency 
were included, and divided into 2 groups. Group A (N: 30) received 
intra venous iron sucrose according to recommended dose 
containing 500mg of iron sucrose for storage, Group B (n=30) 
received intramuscular iron dextran. Mean Hb in group A was 
8.0+/- 1.1gm/dl and in group B was 8.8+/- 0.9gm/dl. In group A 
and B initial Hb was assessed 3 weeks after therapy which showed 
an average rise of 2.8gm/dl in group A and 1.4 gm/dl group B. 
Target Hb level of 11gm/dl was achieved in 80% of group A, 28% 
of group B patients. In group A one patient had moderate 
abdominal pain, 2 had weakness and shivering, 3 had phlebitis but 
none of the patients discontinued the therapy due to adverse effects. 
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In group B majority complained of pain at the injection site, in 
which 5 patients dropped out from study due to intolerance. They 
concluded that I.V iron therapy is safe, convenient and more 
effective than I.M iron therapy; hence I.V iron therapy can replace 
blood transfusion in antenatal period.   
Breyman et al conducted a prospective randomised open 
study evaluated the efficacy and safety of intravenous iron sucrose 
with or without recombinant human erythropoietin in correcting 
iron deficiency anaemia (Hb <10gm/dl) in pregnant women ie. 
gestational age (> 21 weeks). 20 patients received recombinant 
human erythropoietin 300 IU/kg and iron sucrose 200mg I.V and 20 
patients received I.V iron sucrose 200mg alone twice weekly for 4 
weeks till a target Hb of 11 gm/dl was achieved. There was 
immediate reticulocyte response and progressive rise in hematocrit 
in both groups. Higher rise in reticulocyte count and rise in 
hematocrit was observed in the group that received combination 
therapy. None required blood transfusion. No serious adverse 
effects were reported. They concluded that intravenous iron sucrose 
alone should be considered first in resistant iron deficiency anaemia 
during pregnancy. Recombinant human erythropoietin may be 
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considered in severe anaemia requiring rapid correction, not 
responding to I.V iron sucrose. 
Al-Momen Ak, al-Mechari A; al-Nuaime L et al in 1996 
conducted an study comparing I.V iron sucrose and oral ferrous 
sulphate, they observed that iron sucrose complex group achieved 
significantly higher Hb level (128.5+/- 6.6gm/dl Vs 111.4 +/- 
12.4g/l) in control group. P < or = 0.001. Iron sucrose complex 
showed no major side effects, but 6% of control group could not 
tolerate ferrous sulphate. 30% had poor compliance in the control 
group. They concluded that iron sucrose complex is safe and 
effective in the treatment of iron deficiency anaemia during 
pregnancy. 
Catherine Gay (2005) concluded that although oral iron is the 
standard treatment for iron deficiency anaemia, it is poorly 
tolerated and has low efficacy in rapid correction of anaemia; But 
I.V iron sucrose is both quick and effective in treating anaemia. 
The average mean rise of Hb was 0.8 gm/dl for oral iron, 3.5 gm/dl 
for blood transfusion and 3.1gm/dl for I.V iron after 14 days. No 
serious adverse effects were noted for I.V iron sucrose. 
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Bayoumeu F, Subiran – Buisset E, Baka NE et al (2002) 
American Journal of obst. and Gynaecology also observed the 
effectiveness, safety and tolerability of I.V iron sucrose compared 
to oral iron for treatment of iron deficiency anaemia in pregnant 
women.  
Chamate E. conducted a study on treatment of iron deficiency 
anaemia in pregnancy and immediate puerperium comparing I.V 
iron sucrose and oral ferrous sulphate and concluded that I.V iron 
sucrose is safe, convenient and more effective with less adverse 
effects and it can replace blood transfusion in antenatal period. 
Al-Wakeel Js, Malik GH, Atmohaya S, et al 1997, also 
confirmed the effectiveness of intravenous iron sucrose in patients 
with iron deficiency anaemia. 
Gabriela Bancaiova, Ursula Von Mandach, Roland 
Zimmerman- European journal of obstet and gynaecology and 
reproductive biology, vol 144 issue2 – June 2009; 135-139- done a 
study  to compare the efficacy and safety of two or three doses of 
intravenous iron sucrose with daily oral ferrous sulphate in the 
prophylaxis of iron deficiency anaemia in pregnant women. 260 
women with singleton pregnancy were randomised between the 21st 
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and 24 th week with either i,v or oral iron group. Of 130 women in 
the i,v group, 75 received 2 doses of 200mg iron sucrose, 55 three 
doses of 200mg iron sucrose. The first dose was administered 
between the 21st and 24th gestational week, the second between the 
28th and 32nd and the third between 35th and 37th week. The women 
of oral group were given oral tablets of 80mg ferrous sulphate 
daily. They concluded that there was no clinically significant 
difference in the haematological maternal and foetal outcomes in 
the parentral route of iron prophylaxis in pregnant women. 
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IRON METABOLISM 
The average daily intake of oral iron is 20mg and the amount 
of iron absorbed ranges normally from 3-6% of the amount 
ingested. (8). 
SOURCES AND CONTENTS OF IRON 
Milk/litre 
• Human milk -  0.5mg 
• Cow’s milk   -  0.02- 0.3 mg 
Foods/100g  
a. pulses 9-11mg 
b. Cereals 4-11mg 
c. Meat, fish 10-25mg 
d. Ripe banana 0.9mg 
e. Mango 1.3 mg 
f. Melon 7.5mg (9) 
ABSORPTION OF IRON 
Iron is absorbed in the ferrous form (Fe2+) but most dietary 
iron is in the ferric form (Fe3+). Most of the iron is absorbed in the 
duodenum and the proximal jejunum. The mucosal cells have the 
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iron binding protein apoferritin which combines with iron and 
stored as ferritin. The iron which enters the plasma is bound to the 
iron transporting polypeptide transferrin. Apoferritin which is 
found in many other cells binds to form ferittin and stored. (8). 
BIOAVAILABILITY OF IRON 
Iron haemostasis is maintained in the short term by increased 
absorption of iron in deficiency situations and the amount of bioavailable 
iron present in the food is important in the long term. (10) 
Food iron is present in most diets in a proportion of 6mg/1000 
calories and is made of two different pools- heam and non-heam iron 
(10). The heam iron absorption is usually not affected by inhibitors. 
The non-heam iron absorption is enhanced by heam, proteins, 
ascorbic acid and fermentation and decreased by inhibitors like 
phytic acid, fibres, calcium, tannins, tea, coffee, chocolate and 
herbal infusions. 
Iron is important in human body because of its occurrence in 
many hematopoietins such as haemoglobin, myoglobin and 
cytochromes(9). 
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ERYTHROPOIESIS 
The formation of red blood cells is subjected to feed back 
control. It is inhibited by a rise in the circulating red cell level to 
supernormal values and is stimulated by anaemia. It is also 
stimulated by hypoxia. (8). 
Decrease in haemoglobin concentration due to various 
reasons causes decrease in arterial oxygen carrying capacity, which 
leads to increased erythropoietin production in kidney which 
stimulates erythropoiesis. 
The reliability of in vitro bioassay is dependent on 
compensating for the modifying influences of other human serum 
components on erythropoietin activity when in vitro procedures are 
employed to measure erythropoietin in serum. (12). 
Pleuripotent stem cell 
↓ 
Committed stem cells  
(Progenitor cell) 
↓ 
GM – CSF erythroid series 
↓ 
Pro erythroblast 
↓ 
21
 
Rapid division 
↓ 
Basophilic normoblast 
↓ 
Polychromatic normoblast 
(Proliferation activity ceases after this stage. It begins to produce 
Hb in the cell. They are called intermediate normoblast). 
↓ 
Orthochromatic normoblast 
(Final stage of maturation of nucleated red blood cells. Active Hb 
synthesis occurs in cytoplasm. 
↓ 
Active extrusion of nucleus. 
↓ 
Reticulocyte 
↓ 
(Biconcave discoid shaped, greater volume and diameter than 
mature red blood cells) 
↓ 
Lose their mitochondria and ribosome over the course of few days, 
lose the basophilic tint. 
↓ 
Mature erythrocytes. 
Transfusions of blood sufficient to raise the haemoglobin 
concentration above normal or prolonged inhalation of elevated 
partial pressure of oxygen results in depression of erythropoiesis in 
keeping with the expected consequences of such feedback system 
on regulation .(Finch et al 1970). 
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IRON DEFICIENCY ANAEMIA 
Iron deficiency anaemia is the most common nutritional 
deficiency in pregnancy followed by folate deficiency anaemia. 
(13). Out of 150 million deliveries occurring annually in the world, 
approximately 6,00,000 women die from the complications of 
pregnancy. Anaemia is responsible for 40-60% of maternal deaths 
in non-industrialised countries. (14). Mothers with anaemia are 
more likely to succumb to the ill effects of haemorrhage, 
susceptible to infection and suffer from congestive cardiac failure. 
(15). 
WHO criteria for diagnosis of anaemia in pregnancy is 
haemoglobin content of <11g/dl (7.45 mmol/l) and hematocrit of 
less than 0.33. CPC (centre for disease control, USA) proposes a 
cut off point of 10.5 g/dl during the second trimester (16). 
ICMR CATEGORIES OF ANAEMIA 
CATEGORY SEVERITY Hb LEVEL (g/dl) 
Mild 10.0 – 10.9 
Moderate 7.0 – 10.0 
Severe < 7.0 
Very severe < 4.0 
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PREVALANCE OF ANAEMIA IN PREGNANCY 
The overall prevalence of anaemia is estimated to 40% of the 
world’s population. The prevalence is 35% for non pregnant woman 
and 51% for the pregnant woman globally and tends to be 3-4 times 
higher in non- industrialised than industrialised countries (17). 
Nearly half of the global total number of anaemic woman live 
in the Indian sub continent and in India alone, the prevalence of 
anaemia during pregnancy may be as high as 88% (18). 
IRON REQUIREMENT IN PREGNANCY 
In an average pregnancy the requirements are  
1. Basal iron  – 280 mg 
2. Expansion of red cell mass  – 570 mg 
3. Transfer to the fetus            – 200 – 350 mg 
4. Placenta                               – 50 -150 mg 
5. Blood loss at delivery          – 100-250 mg 
After deducting the iron conserved by amenorrhoea (240 – 
480 mg) an additional 500 to 600 mg iron is required in pregnancy 
or 4-6 mg per day of absorbed iron that is 2.5 mg per day in early 
pregnancy, 5.5 mg per day from weeks 20 – 32 and 6-8 mg per day 
from weeks 32 onwards (19). 
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CAUSES FOR HIGH PREVALANCE OF IRON DEFICIENCY 
ANAEMIA 
1. Conception of low bioavailability diet. Iron deficiency 
was higher in both Hindu vegetarian and Muslim halal 
meat eaters, where the animal is slaughtered by cutting 
its carotid artery and bleed to death. (20) 
2. Defective iron absorption due to worm infestation, 
amoebiasis and giardiasis is upto 40% and is a 
significant cause of abnormal iron metabolism and 
anaemia. (21) 
3. Multiple pregnancies where the woman enters 
pregnancy with little or no iron reserve which is 
compounded by closely spaced pregnancies and 
prolonged lactation (22). 
STAGES OF IRON DEFICIENCY ANAEMIA 
Stage I: Negative iron balance 
Demands for iron exceed the body’s ability to absorb iron from 
diet. 
Normal Hb / hematocrit level, Normal RBC indices 
Serum Ferritin < 20ng/ml 
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Stage II: Iron deficient Erythropoiesis 
When stores become depleted serum iron begins to fall, total 
iron binding capacity rises gradually and once the transferrin falls 
to 15 to 20%, Hb synthesis becomes impaired.  
Stage III: Iron deficiency anaemia 
Peripheral picture reveals microcytic and hypochromic cells 
appearing as vacuolated red blood cells with reticulocytes in 
circulation. Gradually Hb and hematocrit begins to fall. Transferrin 
saturation < 15%. 
EFFECT OF ANAEMIA IN PREGNANCY 
FETAL/PLACENTAL MATERNAL 
Prematurity Reduced blood reserve 
Premature uterine 
contractions  
Low exercise and mental 
performance 
Amnion rupture Cardiovascular strain 
Growth retardation Tiredness 
Abnormal trophoblast 
invasion  
Reduced immune function, infection 
Fetal programming Negative thermo regulation 
Disease in new born Increased rate of blood 
transfusion(25) 
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Increased incidence of preterm labour (28.2%), pre-eclampsia 
(31.2%) and sepsis have been associated with anaemia (24). During 
labour there is an increased incidence of postpartum haemorrhage 
and congestive cardiac failure. During puerperium there is an 
increased chance of puerperal sepsis, subinvolution, failing 
lactation and venous thrombosis. 
Fetuses tend to have decreased iron stores due to depletion of 
maternal stores. Adverse perinatal outcome in the form of preterm 
and small for gestational babies and increased perinatal 
mortality.(24) 
CLINICAL FEATURES 
 
1. Mild anaemia may not have any effect on pregnancy 
2. Moderate anaemia may cause increased weakness, lack 
of energy, fatigue, and poor work performance 
3. Severely anaemic woman may have palpitations, 
tachycardia, breathlessness, increased cardiac output 
leading on to cardiac stress which can cause 
decompensation and cardiac failure which may be fatal 
(15,20, 21, 23). 
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SIGNS 
There may be no signs in mild anaemia. There may be pallor, 
glossitis and stomatitis. Patient may have oedema due to 
hypoprotinemia. Soft systolic murmur can be heard in the mitral 
area due to hyperdynamic circulation. There can be fine crepitation 
at the base of lungs due to congestion. 
DIAGNOSIS 
Haemoglobin estimation is the most practical method of 
diagnosis of anaemia. Though various methods like Taliquists 
method, copper sulphate method and sahli’s method available, 
cyanmethhaemoglobin method appears to be the most accurate. 
(26). 
Peripheral blood smear is another bedside indicator of 
diagnosis of anaemia which will also differentiate between iron 
deficiency anaemia, megaloblastic anaemia and haemolytic 
anaemia. Mean corpuscular volume, mean corpuscular haemoglobin 
and mean corpuscular haemoglobin concentration are all low in the 
iron deficiency anaemia. (20). Although the assessment of iron 
status in human population is advanced compared with other 
nutrients, there is still a large uncertainty about absolute diagnosis 
during pregnancy. (27). 
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 Parameters Normal -ve iron balance
Iron deficient 
erythropoiesis
Iron 
deficiency 
anaemia 
Marrow iron 
status 
1 -3+ 0 – 1+ 0 0 
Serum ferritin 
(ng/ml) 
50 – 200 <20 <15 <15 
TIBC(mg/dl) 300 –360 >360 >380 >400 
Serum 
iron(mg/dl) 
50 – 150 N <50 <30 
Saturation (%) 30 – 50 N <20 <10 
Marrow 
sideroblast(%) 
40 – 60 N <10 <10 
RBC 
protoporphyrin 
(mg/dl) 
30 – 50 N >100 >200 
RBC 
morphology 
N N N 
Microcytic 
hypochromic
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ORAL IRON PROHYLAXIS IN PREGNANCY 
The policy of oral iron prophylaxis varies in different 
countries. 
The WHO recommendation is based on the prevalence of 
anaemia. 60 mg of elemental iron with 400 microgram of folic acid 
per day is recommended for 6 months where the prevalence of 
anaemia in pregnancy is <40% and this dose to be supplemented for 
another 3 months postpartum in areas where the prevalence is 
>40%. (19) 
The National Nutritional Anaemia Control Programme of 
India recommends 100 mg of elemental iron plus 500 microgram of 
folic acid for prophylactic supplementation for a minimum of 100 
days starting in the second trimester and double this dosage for the 
treatment of anaemia i.e. 200 mg of elemental iron and 1000 
microgram of folic acid. (28). 
TREATMENT 
The most common cause of anaemia in pregnancy is due to 
iron deficiency. Iron treatment can be given by mouth, or an 
injection into the muscle (intramuscular) or into the vein 
(intravenous). (29). 
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Traditional therapy which is based on either oral 
administration of iron or blood transfusion or both has had 
drawbacks. The efficacy of orally administered high dose iron was 
limited by the high incidence of side effects and thus non 
compliance whereas blood transfusion remains a last resort because 
of patient choice and the risk of infection, immunologic impact and 
transfusion reaction. (6) 
Recently there is increasing interest on alternative therapeutic 
option which includes use of parentral iron sucrose complex and 
recombinant human erythropoietin. (30, 31, 32, 33). 
Parentral iron sucrose complex has several advantages 
because it has a low allergenic properties with a extremely low 
incidence of severe side effects such as anaphylactic reactions 
(34,35) 
Iron sucrose complex has a high availability for 
erythropoeisis, little renal excretion (<5%) and low tissue 
accumulation and toxicity. (36). 
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PHARMACOLOGY OF IRON SUCROSE 
IRON SUCROSE 
Chemical Formula 
[Na2 Fe5O8 (OH) 3 (H2o)]n . m(C12 H22 O11) 
Iron sucrose is a brown, sterile, aqueous complex of 
polynuclear iron (III) hydroxide in sucrose containing 20mg 
elemental iron per ml. 
The sterile solution has an osmolarity of 1250 mosm/l. The 
product does not contain preservatives.  
Molecular wt: 34,000 – 60,000 daltons  
pH                  : 10.5 – 11.1 
MECHANISM OF ACTION 
Following intravenous administration, it is dissociated into 
iron and sucrose by reticuloendothelial system and iron is 
transferred from the blood into pool of iron in the liver and bone 
marrow. Ferritin sequesters iron in a nonionic form from which iron 
is easily available.  
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PHARMACOKINETICS 
Its iron component exhibits first order kinetics 
Elimination t ½ : 6 hrs 
Total clearance : 1.2 litres / hour 
Non – steady state apparent volume of distribution  :  10 lit 
Steady state apparent volume of distribution : 7.9 lit. 
DISTRIBUTION 
In healthy adults, its iron component appears to distribute 
mainly in blood and to some extent in extra cellular fluid.  
ELIMINATION 
The sucrose component is eliminated mainly by urinary 
excretion. Some iron is also eliminated in the urine. (approximately 
5%) 
SIDE EFFECTS 
Headache, fever, pain, asthenia, malaise, abdominal pain. 
INTERACTION  
Should not be administered concomitantly with oral iron 
preparation since the absorption of oral iron may be reduced. 
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CONTRAINDICATIONS  
1. Evidence of iron over load. 
2. Anaemia not caused by iron deficiency  
3. Known hypersensitivity to I.V iron sucrose (or) any of 
its inactive compounds. 
METHOD AND ROUTE OF ADMINISTRATION 
No test dose is required 
1. Slow IV injection 
100mg (2amp) to be given undiluted over a period of 2 – 5 min. 
2. Slow IV infusion 
100mg (2amp) to be diluted with 100ml of normal saline 
immediately prior to infusion and to be infused over a period of 
atleast 15min (6mg/min). 
DOSAGE FREQUENCY 
100mg/day given on alternate days until the required dose is 
infused. 
Chandler et al observed that optimal doses of 200 – 300mg 
infused intravenously over 2 hrs were well tolerated and safe. 
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Patients who received a dose of 400 – 500mg intravenously over 2 
hrs experienced hypotension, nausea, and low back pain.  
SUPPLY AND STORAGE 
Supplied as 2.5ml single dose vial. Each 2.5ml vial contains 
50mg of elemental iron (20mg/ml) that is packaged in carton 
containing 10 single dose vials. Stored at 250C. Excursions 
permitted to 15 – 300C. 
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AIM OF THE STUDY 
 
1. To determine the efficacy and tolerability of the intravenous 
iron sucrose in the treatment of iron deficiency anaemia in the 
postpartum period. 
2. To determine the safety of iron sucrose in the treatment of 
iron deficiency anaemia in the postpartum period. 
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MATERIALS AND METHODS 
This study was conducted in Institute of Obstetrics and 
Gynaecology, Madras Medical College, Chennai. Fifty (50) 
postnatal patients both after vaginal and caesarean section with iron 
deficiency anaemia within the first 48 hours with haemoglobin 
percentage between 6 g/dl and 8g/dl were selected and included in 
this study. 
INCLUSION CRITERIA 
1. Age > 18 years 
2. Diagnosis of postpartum anaemia with Hb% equal to or 
greater than 6 g/dl and less than 8 g/dl. 
EXCLUSION CRITERIA: 
1. History of  allergy to iron containing medications 
2. History of allergic conditions or bronchial asthma 
3. Thalassemia 
4. History of bleeding tendency 
5. Non iron deficient anaemia 
Blood investigations were sent for the patients who looked 
clinically anaemic within the first 48 hours of either vaginal or 
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caesarean delivery, which includes Hb%, PCV, MCV and tests to 
confirm iron deficiency anaemia by peripheral smear, serum iron 
and total iron binding capacity. 
Hb%, PCV, MCV were analysed by automatic cell counter 
and serum iron and total iron binding capacity were calculated 
using semi auto analyser ERBA CHEM 5 PLUS V2. 
Those patients with iron deficiency anaemia were included in 
this study. An informed consent was obtained, a detailed history 
taking and a complete general examination was done. 
METHOD OF THE STUDY 
The dosage of iron required for each individual patient is 
calculated using the formula 
(Target Hb% - patient Hb %) in gm% * 2.4 *weight in kg 
Test dose is not needed. The patients were given 100 mg of 
elemental iron diluted in 100 ml of 0.9 % normal saline and infused 
over 15 minutes every alternate day (not more than 3 days in a 
week) until the required dosage is infused. 
OBSERVATION 
During therapy the following parameters were monitored. 
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1. Vitals – temperature, pulse rate, blood pressure 
2. Adverse effects like nausea, vomiting, abdominal pain, 
chills, etc 
3. Anaphylactic reactions 
The following investigations were done before starting 
therapy, 
1. Haemoglobin in g/dl 
2. PCV 
3. MCV 
4. Serum Iron 
5. Total iron binding capacity 
6. Peripheral smear 
Patients were discharged after infusing the required dose of 
iron and asked to attend the postnatal clinic after four weeks of 
therapy and the following parameters were assessed. 
1. Haemoglobin in g/dl 
2. Hematocrit 
3. MCV 
4. Serum iron 
5. TIBC. 
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RESULTS 
Fifty postnatal women after confirming iron deficiency 
anaemia were included in this study and the required dosage of iron 
was infused intravenously in the form of iron sucrose complex. 
CHARACTERISTICS OF THE CASES STUDIED: 
Table: 1: AGE DISTRIBUTION 
AGE N PERCENTAGE 
<= 20 4 8% 
21 – 25 26 52% 
26 – 30 16 32% 
>30 4 8% 
TOTAL 50 100% 
 
Among the fifty(50) women studied, 8% (4/50) were less than 
or equal to 20 years , 52% (26/50) of the patients belong to the age 
group between 21 - 25 years, 32% (16/50) of the patients belong to 
the age group between 26 – 30 years and 8% (4/50) belong to age 
group above 30 years. The mean age group in our study was 24.94 
years.  
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Table: 2: SOCIO ECONOMIC STATUS 
SOCIO ECONOMIC CLASS N PERCENTAGE 
CLASS I - - 
CLASS II - - 
CLASS III - - 
CLASS IV 8 16% 
CLASS V 42 84% 
TOTAL 50 100 
 
Among the fifty patients in our study 84% (42/50) belonged 
to the class V socio economic status who were more prone for 
nutritional deprivation and 16% (8/50) belonged to the class IV 
socio economic status and none belonged to the class I, II and class 
III. 
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Table- 3: BOOKING STATUS: 
BOOKING STATUS N PERCENTAGE 
BOOKED 36 72% 
UNBOOKED 14 28% 
 50 100% 
Among the fifty patients included in our study 72% (36/50) 
were booked and 28% (14/50) were unbooked. 
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Table - 4: PARITY 
PARITY N PERCENTAGE 
PARA I 16 32% 
PARA II 28 56% 
PARA III 06 12% 
 50 100% 
Among the fifty postnatal patients included in our study 32% 
(16/50) were primipara and 68% (34/50) were multipara. Among 
them 56% (28/50) were para two and 12% (6/50) were para three. 
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Table - 5: MODE OF DELIVERY 
S.NO MODE OF DELIVERY NO PERCENTAGE
1 Labour natural 11 22% 
2 Labour natural with episiotomy 16 32% 
3 Labour natural with LP 1 2% 
4 Emergency LSCS 10 20% 
5 Emergency repeat LSCS 3 6% 
6 Emergency repeat LSCS with St. 9 18% 
  50 100% 
Among the fifty postnatal patients in our study 56% (28/50) 
delivered vaginally and 44% (22/50) were delivered by caesarean 
section. Among the vaginal deliveries 22% (11/50) delivered as 
labour natural with intact perineum, 32% (16/50) delivered by 
labour natural with episiotomy, and 2%(1/50) delivered by labour 
natural with lacerated perineum. Among the caesarean sections 20% 
(10/50) were emergency caesareans, 6%(3/50) were emergency 
repeat caesareans and 18%(9/50) were emergency repeat caesarean 
sections with sterilisation. 
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Table - 6: CHANGE IN HAEMOGLOBIN % 
 N MEAN Hb% STD. DEVIATION
Before treatment 50 7.3020 0.63455 
After treatment 50 10.9040 0.90935 
Change in Hb%  3.6020 0.63551 
p Value p = 0.000 significant 
 
Mean haemoglobin among the fifty patients before starting 
the therapy was 7.3020 g/dl and the mean haemoglobin % at the end 
of one month of completing the therapy was 10.9040 g/dl. The rise 
in mean haemoglobin i.e. the difference in the mean haemoglobin 
before and after treatment was 3.6020 g/dl. The p value is 0.000 
which is statistically significant. 
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Table - 7: CHANGE IN HEMATOCRIT 
 N MEAN PCV STD.DEVIATION
Before treatment 50 24.3520 3.06802 
After treatment 50 33.0900 2.17549 
Change in mean PCV  8.7380 2.66817 
p Value p=0.000 
significant 
 
The mean hematocrit of the fifty patients studied before 
starting the treatment was 24.3520 with a standard deviation of 
3.06802. The mean hematocrit after completing the therapy was 
33.0900 with a standard deviation of 2.17549. The difference in the 
mean hematocrit was 8.7380 with a p value of 0.000 which is 
statistically significant 
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Table - 8: CHANGE IN MCV 
 N MEAN MCV STD.DEVIATION
Before treatment 50 73.2660 5.63269 
After treatment 50 86.8200 3.12782 
Change in mean MCV  13.5540 5.40110 
p Value P= 0.000 
Significant 
  
The mean MCV (Mean Corpuscular Volume) of the fifty 
patients before starting the treatment was 73.2660 with a standard 
deviation of 5.63269. The mean MCV after the completion of the 
treatment was 86.8200 with a standard deviation of 3.12782. The 
difference in the mean MCVs was 13.5540 with the p value of 
0.000 (p<0.05) which is statistically significant. 
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Table - 9: CHANGE IN SERUM IRON 
 N MEAN SERUM IRON 
STD 
DEVIATION 
Before treatment 50 57.9560 5.11744 
After treatment 50 96.7720 7.56180 
Change in mean  38.8160 7.32606 
p Value p=0.000 
Significant 
 
The mean serum iron of the fifty patients before starting the 
treatment was 57.9560 with a standard deviation of 5.11744. The 
mean serum iron after completion of the therapy was 96.7720 with 
a standard deviation of 7.56180. The difference in the mean serum 
iron values was 38.8160 and p value was 0.000 (p<0.05) which was 
statistically significant. 
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Table - 10: CHANGE IN TIBC 
 N MEAN TIBC STD.DEVIATION 
Before treatment 50 399.0300 21.90894 
After treatment 50 269.2600 36.98417 
Change in mean  129.7700 38.87024 
p Value p= 0.000 
significant 
The mean total iron binding capacity of the fifty patients 
before starting the treatment was 399.0300 with a standard 
deviation of 21.90894. The mean total iron binding capacity after 
the completion of the therapy was 269.2600 with a standard 
deviation of 36.98417. The difference in the mean total iron 
binding capacity before and after treatment was 129.7700 and the p 
value was 0.000 (p<0.05) which was statistically significant. 
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Table - 11: CHANGE IN PERCENT SATURATION 
 N MEAN % SATURATION STD.DEVIATION
Before treatment 50 14.4780 1.63860 
After treatment 50 36.7406 6.62209 
Change in mean  22.2626 6.12970 
p Value p= 0.000 
Significant 
The mean percent saturation of the fifty patients before 
starting the treatment was 14.4780% with a standard deviation of 
1.63860. The mean percent saturation after the completion of the 
therapy was 36.7406 with a standard deviation of 6.62209. The 
difference in the two means was 22.2626 and the p value was 0.000 
(p<0.05) which was statistically significant. 
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TABLE - 12: ADVERSE EFFECTS OF THE DRUG 
S.NO ADVERSE REACTIONS N PERCENTAGE 
1 Head ache 1 2% 
2 Nausea/vomiting - - 
3 Abdominal pain - - 
4 Chills and rigors 3 6% 
5 Joint pain - - 
6 Thrombophlebitis 2 4% 
7 Pain at injection site - - 
8 Anaphylactic reactions - - 
9 No side effects 44 88% 
Among the fifty (n=50) postnatal patients in this study, the 
side effects were very minimal and seen in only 12% (6/50). They 
were headache in 2% (1/50) patients, chills and rigors in 6% (3/50) 
and thrombophelibitis in 4% (2/50) patients. There were no 
anaphylactic reactions noted in the study group. There were no 
adverse effects noted in 88% (44/50) of the patients. 
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DISCUSSION 
In our study fifty postnatal patients with iron deficiency 
anaemia were selected according to the inclusion and the exclusion 
criteria stated in the methodology. The iron required is calculated 
and given intravenously in the form of iron sucrose complex and 
followed up after 30 days and the results are analysed. 
In our study 8% (4/50) of the patients were less than or equal 
to 20 years , 52% (26/50) of the patients belong to the age group 
between 21 - 25 years, 32% (16/50) of the patients belong to the 
age group between 26 – 30 years and 8% (4/50) belong to age group 
above 30 years. The mean age group in our study was 24.94 years.  
In our study 84% (42/50) belonged to the class v socio 
economic status who are more prone for nutritional deprivation and 
16% (8/50) belonged to the class Iv socio economic status and none 
belonged to the class I, II and class III. Hence all were in the low 
socio economic status. 
In our study 72% (36/50) were booked and 28% (14/50) were 
unbooked. 
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In our study 32% (16/50) were primipara ,56% (28/50) were 
para two and 12% (6/50) were para three. Majority were in the 
multiparous group 68% (34/50). 
COMPARISION OF OUTCOME PARAMETERS 
Change in Haemoglobin % 
In our study which included fifty postnatal patients the mean 
haemoglobin before starting treatment was 7.3020 and after four 
weeks of treatment was 10.9040 with a p value of 0.000 (p<0.05) 
which was statistically significant. The average raise in the Hb% in 
the four weeks time was 3.6020 with a p value <0.05 which was 
statistically significant. 
According to a study by N Bhandal R Russel et al at 
Department of Anaesthesia, Nuffield department of anaesthetics, 
John padcliffe hospital, Oxford, UK, a prospective randomised 
control trial which included forty four (44) postnatal women with 
Hb<9g/dl at 24 – 48 hours post delivery. The mean Hb% before 
starting the therapy was 7.5g/dl and at the 40th day post treatment 
was 11.2 g/dl with a p value of <0.01 which was statistically 
significant. Our study was comparable to this study.  
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According to another study by C Giannoulis, A Danniilides, T 
Tantanosis et al art Department of Obstetrics and Gynaecology , 
Aristotle University of Thessaloniki, Greece – which included one 
hundred and four anaemic postpartum women with Hb < 8g/dl and 
ferritin <10 microgram /dl. The study compared the effect of 
intravenous iron sucrose over oral iron therapy at the end of four 
weeks. The increase in the mean Hb% was 4.6g/dl and mean ferritin 
level was 105mg/dl with a p value of 0.0001 which was statistically 
significant. Our study was comparable to this study. 
Our study could be compared to a study by A.Dede, D.Uygut 
et al at the Zakai Tahi Burak Women’s Health Education and 
Research Hospital, Division of Perinatology, Turkey, which 
included seventy five (n=75) postnatal women with Hb <9g/dl after 
delivery whether vaginal or caesarean and compared the effect of 
intravenous iron sucrose complex versus oral ferrous sulphate and 
compared the results at the end of 28 days. The mean Hb% at the 
start of treatment was 8.2+/- 0.6g/dl in both the groups. But the 
mean raise in Hb% at the end of 28 days was 12.5+/-1.6g/dl and 
11.8+/-0.7 g/dl in the intravenous and oral group respectively. P 
value was 0.200 which was not significant. However the raise in 
mean Hb in the intravenous group was 4.3g/dl. 
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CHANGE IN HEMATOCRIT 
The mean hematocrit of the fifty patients studied before 
starting the treatment was 24.3520 with a standard deviation of 
3.06802. The mean hematocrit after completing the therapy was 
33.0900 with a standard deviation of 2.17549. The difference in the 
mean hematocrit was 8.7380 with a p value of 0.000 (P<0.05) 
which is statistically significant 
CHANGE IN MCV 
In our study the mean MCV (Mean Corpuscular Volume) of 
the fifty patients before starting the treatment was 73.2660 with a 
standard deviation of 5.63269. The mean MCV after the completion 
of the treatment was 86.8200 with a standard deviation of 3.12782. 
The difference in the mean MCVs was 13.5540 with the p value of 
0.000 (p<0.05) which is statistically significant. 
Our study could be compared to a study by A.Dede, D.Uygut 
et al at the Zakai Tahi Burak Women’s Health Education and 
Research Hospital, Division of Perinatology, Turkey, which 
included seventy five (n=75) postnatal women with Hb <9g/dl after 
delivery whether vaginal or caesarean and compared the effect of 
intravenous iron sucrose complex versus oral ferrous sulphate and 
compared the results at the end of 28 days. The mean MCV before 
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starting the treatment was 51.6+/- 7.2 and the mean MCV at 28 
days post treatment was 84.9+/-2.2 and the mean raise was 33.3 
which is significant. 
In another study by Mrs. Khurshid shabir Raja et al, Jouranl 
of Pakisthan Med.Assoc. volume 28. Number 2 July – Dec 2003, 
which included fifty pregnant women with iron deficiency anaemia 
(Hb < 8g/dl), the mean MCV before starting the treatment was 65fl 
and mean MCV after the treatment was 75fl. The raise in mean 
MCV was 10fl with a p value <0.05 which is statistically 
significant. This is comparable to our study. 
CHANGE IN SERUM IRON 
In our study the mean serum iron of the fifty patients before 
starting the treatment was 57.9560 with a standard deviation of 
5.11744. The mean serum iron after completion of the therapy was 
96.7720 with a standard deviation of 7.56180. The difference in the 
mean serum iron values was 38.8160 and p value was 0.000 
(p<0.05) which was statistically significant. 
Our study could be compared to a study by A.Dede, D.Uygut 
et al at the Zakai Tahi Burak Women’s Health Education and 
Research Hospital, Division of Perinatology, Turkey, which 
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included seventy five (n=75) postnatal women with Hb <9g/dl after 
delivery whether vaginal or caesarean and compared the effect of 
intravenous iron sucrose complex versus oral ferrous sulphate and 
compared the results at the end of 28 days. The mean serum iron 
values before starting the treatment was 42.8+/-29.3 and the mean 
serum iron 28 days post treatment was 86.2+/-44.3. 
CHANGE IN TIBC 
The mean total iron binding capacity of the fifty patients 
before starting the treatment was 399.0300 with a standard 
deviation of 21.90894. The mean total iron binding capacity after 
the completion of the therapy was 269.2600 with a standard 
deviation of 36.98417. The difference in the mean total iron 
binding capacity before and after treatment was 129.7700 and the p 
value was 0.000 (p<0.05) which was statistically significant. 
Our study could be compared to a study by A.Dede, D.Uygut 
et al at the Zakai Tahi Burak Women’s Health Education and 
Research Hospital, Division of Perinatology, Turkey, which 
included seventy five (n=75) postnatal women with Hb <9g/dl.The 
total serum iron binding capacity before starting the treatment was 
411.0+/-105.2 and the mean TIBC after 28 days of treatment was 
287.2+/-89.1. 
57
 
CHANGE IN PERCENT SATURATION 
In our study the mean percent saturation of the fifty patients 
before starting the treatment was 14.4780% with a standard 
deviation of 1.63860. The mean percent saturation after the 
completion of the therapy was 36.7406 with a standard deviation of 
6.62209. The difference in the two means was 22.2626 and the p 
value was 0.000 (p<0.05) which was statistically significant. 
ADVERSE REACTIONS 
In our study which included fifty (n=50) postnatal patients in 
this study, the side effects were very minimal and see in only 12% 
(6/50). They were head ache in 2% (1/50) patients, chills and rigors 
in 6% (3/50) and thrombophelibitis in 4 (2/50) patients. There were 
no anaphylactic reactions noted in the study group. There were no 
adverse effects noted in 88% (44/50) of the patients. 
In a study by N Bhandal,R Russel et al , no serious adverse 
effects were reported. Five women (23%) complained of metallic 
taste during the infusion of the drug which is not noted in our 
study. Four women (18%) complained of facial flushing, describing 
it as warm tingling sensation, this was reported as ‘not unpleasant’. 
There was no hemodynamic disturbance observed either during 
infusion or after infusion. 
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In a study by C Giannoulis, A Danniilides, T Tantanosis et al 
at Department of Obstetrics and Gynaecology, Aristotle University 
of Thessaloniki, Greece, reported that iron sucrose is quite safe for 
the liver in daily doses of 100mg, in comparison with other iron 
supplementation. Rare anaphylactic reactions because of the use of 
iron sucrose have been reported in about 0.002% of cases. 
In another study by Dr. Mrs. Khurshid shabir Raja et al, 
published in Journal of Pakistan Med. Assoc. volume 28. Number 2 
July – Dec 2003, which included fifty pregnant women with iron 
deficiency anaemia (Hb < 8 g/dl), only two patients, had mild 
reactions. One had pain in the epigastrium and the other had 
restlessness. No patient had reactions of severe nature, threatening 
the patient’s life and requiring discontinuation of infusion. 
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SUMMARY 
In our study fifty postnatal patients with iron deficiency 
anaemia were selected according to the inclusion and the exclusion 
criteria stated in the methodology. The iron required is calculated 
and given intravenously in the form of iron sucrose complex and 
followed up after 30 days and the following parameters were 
analysed. 
1. Haemoglobin in g/dl. 
2. Hematocrit. 
3. Mean corpuscular volume. 
4. Serum iron.  
5. Total iron binding capacity. 
6. Percent saturation. 
 
The results of the study are tabulated, analysed and 
summarised as follows; 
1. Majority of the patients around 52% (26/50) belong to 
the age group between 21 – 25 years. 
60
 
2. Almost three fourth (72%) of the patients were booked 
patients. 
3. Majority of the patients (84%) belongs to the class V 
socio economic status. 
4. Majority of the patients were multipara (68%) and 
among them para 2 is the major population (56%) 
5. Mean raise in haemoglobin % after 30 days of treatment 
was 3.60 with a p value <0.05 which is statistically 
significant. 
6. Average raise in the mean hematocrit was 8.73 after 30 
days of treatment with a p value <0.05 which is 
statistically significant. 
7. Mean raise in the Mean Corpuscular Haemoglobin was 
13.55 fl with a p value of <0.05 which is statistically 
significant. 
8. Mean raise in the serum iron value was 38.82 with a p 
value <0.05 which is statistically significant. 
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9. Mean change in the total iron binding capacity is 
129.77 with a p value of <0.05 which is statistically 
significant 
10. Mean change in the percent saturation was 22.26 with a 
p value <0.05 which is statistically significant. 
11. The side effects were very minimal in our study group 
(12%). The side effects profile was also very mild 
which included headache in one patient, chills and 
rigors in three patients and thrombophlebitis in two 
patients. No anaphylactic reactions occurred. 
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CONCLUSION 
1. Intravenous iron sucrose complex is highly efficacious 
in improving the haemoglobin %, hematocrit and the 
serum iron values in the treatment of iron deficiency 
anaemia in the postnatal women. 
2. Iron sucrose infusion was well tolerated and safe, there 
were no major adverse reactions 
To conclude intravenous iron sucrose complex is safe, 
convenient and more effective mode of treatment of iron deficiency 
anaemia in postnatal women.  
It could be used to reduce the number of blood transfusions in 
the postnatal period in asymptomatic women with Hb% between 6 
and 8 g/dl. 
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ABBREVATIONS 
WHO - World Health Organisation 
Hb - Haemoglobin 
MCV - Mean Corpuscular Volume 
PCV - Packed Cell Volume 
RBC - Red Blood Corpuscles 
MCHC - Mean Corpuscular Haemoglobin Concentration 
TIBC - Total Iron Binding Capacity 
Fe2+ - Ferrous Iron 
Fe3+ - Ferric  Iron 
I.V - Intravenous 
LP - Lacerated Perineum 
LSCS - Lower Segment Caesarean Section 
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KEY TO MASTER CHART 
MOD - Mode of Delivery 
1 –  Labour Natural 
2 – Labour Natural with Episiotomy 
3 – Labour Natural with Lacerated Perineum 
4 – Emergency LSCS 
5 – Emergency  repeat  LSCS 
6 – Emergency repeat LSCS with Sterilisation 
OS -  Obstetric Score 
PS -  Peripheral Smear 
MH -  Microcytic Hypochromic picture 
TC -  Total Count 
SE -  Side Effects 
N - No Side Effects 
H - Headache 
T - Thrombophlebitis 
C -  Chills and Rigors 
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PROFORMA 
STUDY OF EFFECTIVENESS, TOLERABILITY AND SAFETY OF 
INTRAVENOUS IRON SUCROSE IN IRON DEFICIENCY ANAEMIA IN 
POSTNATAL WOMEN. 
Name  :     Age : 
IP No  :     Address: 
Occupation :     Phone no: 
Income : 
Socioeconomic Class : 
Obstetric score  :    
Para :       
Live : 
Abortions: 
Presenting complaints: 
H/o Easy fatiguability / giddiness 
H/o Hook worm infestation 
H/o Bleeding per vaginum 
H/o Hematemesis / malena 
H/o Anorexia / indigestion 
H/o Multiple pregnancy 
H/o Breathlessness 
H/o Swelling of legs 
H/o Puffiness of face 
H/o Iron intolerance 
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Past H/o: 
H/o Blood loss in between pregnancy 
H/o DM, HT, Asthma, epilepsy, TB 
Menstrual H/o: 
Age at menarche : 
Cycles  :   Regular  Irregular 
flow  : 
Marital H/o: 
M /s : 
Obstetric History : 
Details about previous pregnancy:  Yes  No 
H/o Antepartum Hemorrhage 
H/o Postpartum Hemorrhage 
H/o Blood Transfusion 
 
Present Pregnancy: 
1. H/o Antepartum Hemorrhage 
2. H/o Postpartum Hemorrhage 
General Examination: 
Features of Chronic anemia :   Yes   No 
1. Pallor   : 
2. Glossitis  : 
3. Facial Puffiness : 
4.  Koilonychia  : 
78
 
VITALS 
Temp: 
PR :      CVS : 
BP :      RS: 
Investigations: 
To confirm iron deficiency anaemia: 
1. Hb  : 
2. Urine  :  Albumin 
    Sugar 
   Deposits 
3. Blood  :  Sugar 
   Urea 
   Serum : Creatinine 
5. Peripheral smear: 
6. MCV 
7. Hematocrit 
8. Stool:  Ova/Cyst 
9. Serum iron: 
10. TIBC: 
11. Percent saturation: 
Iron Requirement: 
Dose of intravenous iron sucrose needed for therapy: 
Parameters monitored during therapy: 
Adverse effects     Yes   No 
1. Anaphylactic reaction 
    (Shivering, Hypotension) 
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2. Nausea / Vomiting 
3. Thrombophlebitis 
4. Abdominal Pain 
5. Diarrhoea 
6. Chills / Rigors  
7. Joint pain 
Post therapy Assessment: 
Parameters assessed 4 weeks post therapy 
1. Hb 
2. MCV 
3. Hematocrit 
4. Serum Iron 
5. TIBC 
6. Percent saturation 
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AGE DISTRIBUTION 
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SOCIO ECONOMIC CLASS 
 
 
82 
BOOKING STATUS 
 
 
 
83 
PARITY 
 
 
84 
MODE OF DELIVERY 
 
 
85 
CHANGE IN HAEMOGLOBIN 
 
 
86 
CHANGE IN HEMATOCRIT 
 
 
87 
CHANGE IN MCV 
 
 
88 
CHANGE IN SERUM IRON 
 
 
89 
CHANGE IN TIBC 
 
 
90 
CHANGE IN PERCENT SATURATION 
 
 
91 
ADVERSE EFFECTS OF THE DRUG 
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SERUM IRON AND TIBC REAGENT KIT 
 
SEMI AUTO ANALYSER –ERBA CHEM PLUS V2  
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CELL COUNTER 
 
IRON SUCROSE – HEMFER 
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Column1Column2 ColumColumnColumColumn6ColumColumColumColum Colum ColumColu Columnolumn1olumnolumn1olumn1olumn2ColumnColu
S.No Name Age IP.No. MOD OS Hb% PCV MCV S.IRONTIBC % sat PS  TC POST TRANSFUSION
 Hb% PCV MCV Sr.Ir TIBC % sat SE
1 Velankanni 24 12608 2 P1L1 7.7 27 72.8 52 390 13 MH 7600 10.9 34.7 88 84 344 24.4 N
2 Saranya 22 12800 6 P2L2 6.5 20 63 50 410 12 MH 9300 9.7 30 86 82.4 345 23.9 N
3 Malar 23 12902 6 P2L2 6.9 24 65 49 395 12.4 MH 9000 9.7 33.3 87 92.5 236 39.1 N
4 Priya 24 13177 2 P1L1 7.3 21.8 76 58 412 14 MH 14700 11.0 34 88 94 240 39.1 N
5 Pavithra 32 13498 6 P3L2 8 26.5 80 62 370 16 MH 14000 12.5 36 92 92 213 43.1 N
6 Gracy 29 13202 4 P1L1 7.5 19.5 78 60 380 15 MH 15500 11.2 34.6 94 99 215 46 H
7 Padmavathy 21 13188 4 P1L1 8 26 78 56 420 13.3 MH 15100 12.5 37.7 94 94 243 38.6 N
8 Kalaiselvi 26 14131 1 P2L1 6.9 22 66 67 450 14.8 MH 17100 10.4 33 88 102 280 36.4 N
9 Jaya 31 12450 2 P2L2 8 27 72 59 412 14.3 MH 10000 11.2 34 90 102 215 47.4 N
10 Subhashini 23 12811 2 P2L2 7.3 27 74 64 401 15.9 MH 14000 10.3 33 82 96 304 31.5 N
11 Amuthavalli 26 12905 4 P1L1 8 27 77 62 410 15.1 MH 14100 10.4 33 83 100 245 40.8 T
12 Roja Rani 26 13645 2 P2L2 8 28 75 60 406 14.7 MH 12000 11.0 34 87 102 250 40.8 N
13 Uma 20 13128 2 P2L2 6.5 23 70 62 395 15.6 MH 15000 9 28 82 96 204 47 N
14 Anandhi 25 13381 2 P3L3 6.5 20 69 68.4 356.3 19 MH 14200 11.2 34 86 98 256 38.2 C
15 Vinodhini 21 13578 2 P1L1 7.4 29.8 78.8 56 376.2 14.8 MH 13100 12.5 37 90 102 260 39.2 N
16 Shakila 30 12853 4 P2L2 8 28 78 68.4 341 19 MH 12100 11.4 34.6 89 98 215 45.5 N
17 Indumathy 24 11750 2 P1L1 8 27 79 60 408 14.7 MH 12000 12 35 90 100 254 39.3 N
18 Abirami 26 13580 2 P2L2 7.4 27 80 52 400 13 MH 15100 10.6 34 86 98 300 32.6 C
19 Thilaga 28 13456 1 P2L2 7.1 26 76 60 390 15.3 MH 14000 11.5 34 89 104 300 34.6 N
20 Devika 22 13396 6 P1L1 8 28 78.7 54 402 13.4 MH 13400 11.5 33 88 114.3 310 36.8 N
21 Vasuki 24 14015 2 P1L1 6.6 20 63 56 370 15 MH 10000 9.4 28 83 98 300 32.6 N
22 Parameshwari 23 14030 4 P1L1 7.3 26 69 64 411 15.5 MH 13100 10.7 33 84 100 250 40 N
23 Thilagavathy 20 16834 1 P1L0 8 27.6 74 62 411 15 MH 11300 11.2 32.8 86 114 245 46.5 N
24 Alamelu 25 16894 1 P1L1 7.8 23.6 76 60 390 15.3 MH 11100 11.1 32 87 98 250 39.2 T
25 Kalavathy 25 16611 1 P2L2A2 6.4 23.8 65 52 410 12.6 MH 12100 10.1 31.6 85 88 300 29.33 N
26 Mariammal 20 16823 6 P1L1 7.4 26 69 62 380 16.3 MH 13100 10.8 31 88 92 280 32.8 N
27 Jayanthy 30 16862 4 P2L2 6.3 22 70 54 410 13.1 MH 14000 9.4 31 82 88 270 32.5 N
28 Sandhya 20 16928 5 P3L2 6.5 20 72 61 390 15.6 MH 12100 10.1 34.7 86 98 240 40.8 N
29 Amudha 22 16902 5 P2L2 7 21 78 60 415 14.4 MH 13200 11.4 35.2 90 108 215 50.2 N
30 Bhau nesha 23 17310 2 P2L2 6.1 20 60 51 400 12.7 MH 14100 9.1 28 85 84 300 28 N
31 Latha 24 18723 1 P2L2 7.4 26 75 52 490 10.6 MH 12100 11.2 33 84 88 305 28.8 N
32 Selvi 23 18757 1 P2L2 6.4 21 68 62 380 16.3 MH 11000 10.1 31 85 90 305 29.5 N
33 Madhumitha 24 18689 1 P2L1A1 7 22 69 62 390 15.8 MH 12000 11.1 33 88 110 288 38.1 N
34 Sandhya 23 19047 1 P2L2 8 27 77 60 400 15 MH 11000 12.7 35 89 99 290 34.1 N
35 Jayanthy 24 19105 1 P2L2 7.4 28 75 60 390 15.3 MH 12000 10.2 33 83 86 310 27.7 N
36 Madhavi 32 19309 6 p2L2 7 26 68 58 410 14.1 MH 13,300 11.3 35 86 103 280 36.7 N
37 Pusparani 24 18080 2 P2L2 8 28 80 60 410 14.6 MH 11100 11.1 33 85 92 300 30.6 C
38 Padmavathy 26 17640 6 P2L2 7.9 28 80 59 390 15.1 MH 13200 11.5 34 85 98 215 45.5 N
39 Vijayalakshmi 24 17277 2 P1L1 6.8 20.1 72 54 400 13.5 MH 10000 11.7 32.8 83 97 313 30.9 N
40 Komala 26 19047 4 P2L1 6.7 19.7 74 58 380 15.2 MH 17100 10.1 29.1 82 88 300 29.3 N
41 Prabha 28 19126 4 P2L2 6.1 20.9 63 46 420 10.9 MH 15400 9.7 30.1 87 92 280 32.8 N
42 Menaka 26 19134 4 P1L1 7.9 22.3 79 56 390 14.3 MH 13200 12.2 34.4 92 102 250 40.8 N
43 Ramya 26 19244 4 P2L3 6.1 18.9 62 52 390 13.3 MH 10100 9.7 30.1 87 92 280 32.8 N
44 Jayanthy 25 19256 5 P2L2 8 25.1 79 60 400 15 MH 11210 11.0 32.9 88 114 240 47.5 N
45 Akhilandeshwar 29 19360 6 P3L2 7.4 23.6 72 59 410 14.3 MH 13400 11.2 34 86 98 300 32.6 N
46 Meharunesha 28 19412 2 P3L3 7.2 23.3 77 60 400 15 MH 17500 11.4 34.1 87 88 290 30.3 N
47 Latha 27 19426 2 P1L1 8 25.1 78 54 400 13.5 MH 13000 11.2 33 84 88 305 28.8 N
48 Thangam 22 19434 1 P2L2A2 7.9 26 79 58 390 14.8 MH 12100 11.4 34.1 87 88 290 30.3 N
49 Malarvizhi 26 19500 6 P2L2 7.5 24 76 46 410 11.2 MH 12100 10.5 31.5 83 89.4 330 27.9 N
50 Janaki 25 19604 3 P3L3 8 28 78 60 390 15.3 MH 11000 12.2 36.3 94 94 243 38.6 N
